With the initial collaboration launching in 2019, Pfizer has since used CytoReasons biological models to enhance research in understanding the immune system as the company develops innovative drugs for immune-medicated and immune-oncology diseases. Due to the collaboration, Pfizer has reportedly gained multiple insights in research and development programs across over 20 diseases.
“We’re pleased to expand our strategic collaboration with CytoReason,” said Mikael Dolsten, Pfizer chief scientific officer and president. “We look forward to continuing our work with the company’s leading scientists, and to leveraging its cutting-edge platform. CytoReason’s biological data allows us to gain deeper insight into the best drug development pathways for patients, resulting in more informed decisions that are timely and cost-effective.”
Under the updated terms of the agreement, Pfizer will make a $20 million equity investment, have options to license CytoReason’s platform and disease models, and fund supplementary project support. Additionally, the deal is, according to CytoReason, potentially worth up to $110 million over the next five years.
The new research agreement and investment will support the ongoing development of additional disease models and the creation of high-resolution models spanning multiple therapeutic areas.
“Pfizer has been a strategic partner of CytoReason since 2019, and we are thrilled to scale our collaboration as one of Pfizer’s trusted AI partners for accelerating drug development,” said David Harel, co-founder and CEO of CytoReason. “This partnership is advancing a significant shift in the biotech industry, and helping drive future R&D for pharmaceutical companies as they continue to use machine learning to develop treatments more efficiently. Transforming complex data into useful actionable insights will potentially provide leading researchers and scientists a roadmap to further develop their drug portfolios.”